The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Moderna continues to cut costs, which could raise questions about the vaccine playbook used during the Covid-19 pandemic.

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA approved.

Robert F. Kennedy Jr., who's nominated to become the next health secretary, asked the federal government to revoke its authorization of all COVID-19 vaccines in May 2021, just as vaccinated Americans ...

Moderna Inc and Takeda ... authorities to recall three batches of COVID-19 vaccine after an investigation found stainless steel contaminants in some vials. Japanese authorities had suspended ...

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.

Moderna has been ... the development of an mRNA vaccine that could be used for bird flu. mRNA technology is the same type that was used in the development of some COVID-19 vaccines.

The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.

The stock is on pace for its lowest close since April 2020, when its Covid-19 vaccine development efforts were gaining steam. Moderna said it now expects full-year 2025 revenue of $1.5 billion to ...

And unlike the other three illnesses that make up the ongoing “quad-demic”—flu, COVID, and respiratory syncytial virus (RSV)—norovirus has no FDA-approved vaccine. Moderna, a Massachusetts ...

Moderna pulled in most of its revenue last year from its COVID-19 vaccine, Spikevax, which brought in more than $3 billion in sales. Regulators also approved a Moderna vaccine for RSV, or ...